Holen Sie sich die Stockscreener-App
0.3672
1.13%
0.0041
Handel nachbörslich:
.35
-0.0172
-4.68%
Schlusskurs vom Vortag:
$0.3631
Offen:
$0.36
24-Stunden-Volumen:
1.31M
Relative Volume:
0.47
Marktkapitalisierung:
$48.10M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-0.2448
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
-4.85%
1M Leistung:
+2.51%
6M Leistung:
-82.92%
1J Leistung:
-83.46%
1-Tages-Spanne:
$0.35
$0.38
1-Wochen-Bereich:
$0.35
$0.4597
52-Wochen-Spanne:
$0.2589
$2.83
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.3672 | 48.10M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | William Blair | Outperform |
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
94,531 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Pallas Capital Advisors LLC - Defense World
Mersana Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Two Sigma Investments LP Has $302,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of “Buy” by Brokerages - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Bank of America Corp DE Sells 36,084 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Up 21.4% in May - Defense World
Millennium Management LLC Increases Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at William Blair - Defense World
Mersana reports promising Phase 1 ADC trial results By Investing.com - Investing.com South Africa
Mersana reports promising Phase 1 ADC trial results - Investing.com India
Mersana Therapeutics Reports Additional Positive Interim Phase 1 - GuruFocus
Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data - GuruFocus
Mersana Therapeutics Reports Encouraging Interim Phase 1 Results for Emiltatug Ledadotin in B7-H4 High Tumors at ASCO 2025 - Nasdaq
Mersana Therapeutics Reports Additional Positive Interim - GlobeNewswire
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in ... - Eagle-Tribune
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - Yahoo Finance
Mersana Therapeutics at TD Cowen Summit: Strategic Updates on Oncology Innovations - Investing.com Canada
Deutsche Bank AG Has $1.20 Million Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
D. E. Shaw & Co. Inc. Sells 477,992 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
BNP Paribas Financial Markets Has $516,000 Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Is Now The Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - Stocksregister
Mersana Therapeutics to Present at Upcoming Investor Conferences - GuruFocus
Mersana Therapeutics Showcases Cancer Drug Pipeline at Goldman Sachs and TD Cowen Healthcare Summits - Stock Titan
Cubist Systematic Strategies LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World
Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN
Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN
MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus
MRSN: Guggenheim Reiterates Buy Rating with $5 Price Target | MRSN Stock News - GuruFocus
Mersana Therapeutics (MRSN) Target Price Increased by Truist | M - GuruFocus
Mersana Therapeutics price target raised to $10 from $9 at Truist - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating - marketscreener.com
Truist raises Mersana stock target to $10, maintains Buy rating By Investing.com - Investing.com Nigeria
Truist raises Mersana stock target to $10, maintains Buy rating - Investing.com Australia
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights - GuruFocus
Earnings call transcript: Mersana Therapeutics reports Q1 2025 loss, stock up 6.14% - Investing.com Nigeria
Mersana Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
CORRECTIONMersana Therapeutics Provides Business Update and A - GuruFocus
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Cancer Drug Shows Strong 31% Response Rate in Latest Trial Data, Reports Q1 Financial Results - Stock Titan
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mersana Therapeutics Inc-Aktie (MRSN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mandelia Ashish | VP, Chief Accounting Officer |
Jan 16 '25 |
Sale |
0.58 |
3,554 |
2,061 |
57,519 |
| Protopapas Anna | Director |
Jan 15 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
176,678 |
| Protopapas Anna | Director |
Jan 16 '25 |
Sale |
0.58 |
8,637 |
5,009 |
168,041 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
19,791 |
0 |
265,721 |
| Lowinger Timothy B | SVP, Chief Sci.&Tech. Officer |
Jan 16 '25 |
Sale |
0.58 |
8,048 |
4,668 |
257,673 |
| Huber Martin H. Jr. | President, CEO |
Jan 15 '25 |
Option Exercise |
0.00 |
11,062 |
0 |
127,389 |
| Huber Martin H. Jr. | President, CEO |
Jan 16 '25 |
Sale |
0.58 |
4,514 |
2,618 |
122,875 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 15 '25 |
Option Exercise |
0.00 |
20,833 |
0 |
129,863 |
| DeSchuytner Brian | SVP, COO & CFO |
Jan 16 '25 |
Sale |
0.58 |
8,470 |
4,913 |
121,393 |
| Carvajal Alejandra | SVP, Chief Legal Officer |
Jan 15 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
83,392 |
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):